In the present study, we found that DCHT was able to greatly alleviate acute intrahepatic cholestasis and protect against cholestasis-induced liver injury without any apparent toxicity in vivo via PPARα activation, thus providing strong evidence that DCHT is a potentially useful therapeutic formula for the prevention and treatment of intrahepatic cholestatic hepatoxicity. This evidence concerns the gene STK39 and intrahepatic cholestasis.